IFP Advisors’s Acadia Pharmaceuticals ACAD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $28.2K | Sell |
1,115
-252
| -18% | -$5.54K | ﹤0.01% | 2751 |
|
|
2026
Q1 | $30.4K | Buy |
1,367
+89
| +7% | +$2.13K | ﹤0.01% | 2543 |
|
|
2025
Q4 | $34.1K | Buy |
1,278
+173
| +16% | +$4.13K | ﹤0.01% | 2411 |
|
|
2025
Q3 | $23.6K | Sell |
1,105
-2,321
| -68% | -$54.9K | ﹤0.01% | 2507 |
|
|
2025
Q2 | $73.9K | Buy |
3,426
+14
| +0.4% | +$260 | ﹤0.01% | 1830 |
|
|
2025
Q1 | $56.7K | Sell |
3,412
-646
| -16% | -$11.7K | ﹤0.01% | 1843 |
|
|
2024
Q4 | $74.5K | Buy |
4,058
+498
| +14% | +$8.04K | ﹤0.01% | 1624 |
|
|
2024
Q3 | $54.7K | Buy |
3,560
+879
| +33% | +$14.7K | ﹤0.01% | 1693 |
|
|
2024
Q2 | $43.6K | Buy |
2,681
+1,231
| +85% | +$19.9K | ﹤0.01% | 1739 |
|
|
2024
Q1 | $26.8K | Buy |
+1,450
| New | +$35.9K | ﹤0.01% | 1846 |
|
|
2023
Q2 | – | Sell |
-1,500
| Closed | -$27.5K | – | 3441 |
|
|
2023
Q1 | $27.5K | Sell |
1,500
-500
| -25% | -$9.52K | ﹤0.01% | 1876 |
|
|
2022
Q4 | $37K | Sell |
2,000
-27
| -1% | -$422 | ﹤0.01% | 2434 |
|
|
2022
Q3 | $38K | Buy |
2,027
+1,500
| +285% | +$24.3K | ﹤0.01% | 2570 |
|
|
2022
Q2 | $10K | Hold |
527
| – | – | ﹤0.01% | 3372 |
|
|
2022
Q1 | $10K | Buy |
+527
| New | +$12.8K | ﹤0.01% | 3372 |
|
|
2021
Q3 | – | Sell |
-152
| Closed | -$4K | – | 3359 |
|
|
2021
Q2 | $4K | Sell |
152
-148
| -49% | -$3.34K | ﹤0.01% | 2523 |
|
|
2021
Q1 | $8K | Buy |
300
+100
| +50% | +$4.4K | ﹤0.01% | 2203 |
|
|
2020
Q4 | $11K | Buy |
+200
| New | +$9.93K | ﹤0.01% | 2022 |
|
|
2020
Q3 | – | Sell |
-22
| Closed | -$950 | – | 2827 |
|
|
2020
Q2 | $1K | Buy |
+22
| New | +$1.06K | ﹤0.01% | 2491 |
|
|
2019
Q1 | – | Sell |
-1,186
| Closed | -$19K | – | 2348 |
|
|
2018
Q4 | $19K | Buy |
1,186
+750
| +172% | +$14.6K | ﹤0.01% | 2156 |
|
|
2018
Q3 | $9K | Buy |
436
+118
| +37% | +$1.86K | ﹤0.01% | 2888 |
|
|
2018
Q2 | $5K | Sell |
318
-518
| -62% | -$9.24K | ﹤0.01% | 3221 |
|
|
2018
Q1 | $25K | Hold |
836
| – | – | ﹤0.01% | 2236 |
|
|
2017
Q4 | $25K | Sell |
836
-1,682
| -67% | -$53.8K | ﹤0.01% | 2265 |
|
|
2017
Q3 | $95K | Buy |
2,518
+475
| +23% | +$15.5K | ﹤0.01% | 1588 |
|
|
2017
Q2 | $57K | Sell |
2,043
-975
| -32% | -$29.1K | ﹤0.01% | 1877 |
|
|
2017
Q1 | $104K | Sell |
3,018
-3,091
| -51% | -$109K | ﹤0.01% | 1470 |
|
|
2016
Q4 | $176K | Sell |
6,109
-2,688
| -31% | -$71.1K | 0.01% | 1116 |
|
|
2016
Q3 | $280K | Buy |
8,797
+2,350
| +36% | +$79.7K | 0.01% | 842 |
|
|
2016
Q2 | $209K | Buy |
+6,447
| New | +$216K | 0.01% | 946 |
|
|
2016
Q1 | – | Sell |
-4,249
| Closed | -$151K | – | 2343 |
|
|
2015
Q4 | $151K | Buy |
+4,249
| New | +$150K | 0.01% | 965 |
|
Other funds holding ACAD
BBA
RI
PAI
IFP Advisors's ACAD Position: Q2 2026 in Review
IFP Advisors reduced its Acadia Pharmaceuticals (ACAD) stake by 18% in Q2 2026, selling an estimated $5.54K and leaving 1,115 shares worth $28.2K. The position accounts for ﹤0.01% of the portfolio, ranked #2751.
IFP Advisors first reported a position in ACAD in Q4 2015 and has held it in 31 quarters since. The position peaked at $280K in Q3 2016. 353 funds tracked by Wall St. Rank hold ACAD as of Q2 2026.
- IFP Advisors held 1,115 shares of Acadia Pharmaceuticals worth $28.2K as of Q2 2026.
- IFP Advisors sold 252 Acadia Pharmaceuticals shares in Q2 2026, an estimated $5.54K.
- Acadia Pharmaceuticals made up ﹤0.01% of IFP Advisors's portfolio in Q2 2026, its #2751 holding.
- IFP Advisors first reported a position in Acadia Pharmaceuticals in Q4 2015 and has held it in 31 quarters since.
- IFP Advisors's Acadia Pharmaceuticals position peaked at $280K in Q3 2016.
- 353 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2026.
Based on IFP Advisors's 13F filing for Q2 2026, filed 20 Jul 2026.